Mohammad Amin, MD
Nephrology · Farmington, MONPI 1851325534
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.2% of the total across 154 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations.
Across 154 payments — averaging $33.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$889
- AstraZeneca$739
- Fresenius USA Marketing, Inc.$701
- Vifor Pharma, Inc.$585
- Travere Therapeutics, Inc.$443
- Otsuka America Pharmaceutical, Inc.$433
- plus $1K from 12 others
What the payments were for
- Travel & lodging$3557%
- Food & beverage$4,62390%
- Education$1463%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 40 | $889 |
| AstraZeneca | 26 | $739 |
| Fresenius USA Marketing, Inc. | 6 | $701 |
| Vifor Pharma, Inc. | 24 | $585 |
| Travere Therapeutics, Inc. | 14 | $443 |
| Otsuka America Pharmaceutical, Inc. | 16 | $433 |
| Mallinckrodt Enterprises LLC | 4 | $334 |
| Calliditas Therapeutics US Inc. | 3 | $216 |
| Baxter Healthcare | 1 | $143 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $134 |
| Vantive US Healthcare LLC | 1 | $117 |
| Amgen(2 entities) | 6 | $111 |
| Outset Medical Inc | 1 | $108 |
| OPKO Pharmaceuticals, LLC | 4 | $61 |
| Akebia Therapeutics Inc | 2 | $35 |
| Ardelyx, Inc. | 2 | $33 |
| Scpharmaceuticals Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$519
- Filspari$254
- ACTHAR$247
- LOKELMA$130
- JYNARQUE$125
- Veltassa$125
- FARXIGA$118
- Renal - PD$117
- LIBERTY SELECT CYCLER$112
- NXSTAGE SYSTEM ONE$112
- TARPEYO$101
How this compares
$5,124 in reported general payments places this provider in the 80th percentile of 253 nephrology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 54 | $148,538 |
| VeltassaPatiromer Calcium Sorbitex | 119 | $140,814 |
| LokelmaSodium Zirconium Cyclosilicate | 62 | $68,776 |
| AuryxiaFerric Citrate | 29 | $52,607 |
| FarxigaDapagliflozin Propanediol | 68 | $44,962 |
| Lanthanum Carbonate | 30 | $35,902 |
| Sevelamer Carbonate | 145 | $24,241 |
| KerendiaFinerenone | 26 | $19,240 |
| Calcitriol | 358 | $3,551 |
| Potassium Chloride | 234 | $3,200 |
| Losartan Potassium | 275 | $2,020 |
| Furosemide | 393 | $2,004 |
| Amlodipine Besylate | 306 | $1,561 |
| Bumetanide | 32 | $1,477 |
| Irbesartan | 98 | $1,248 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $701 | $148,53854 claims |
| AstraZenecaLokelma, Farxiga | $739 | $113,738130 claims |
| Akebia Therapeutics IncAuryxia | $35 | $52,60729 claims |
| BayerKerendia | $889 | $19,24026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 253 nephrology providers in Missouri.
Other nephrology in Farmington
- Bishan ChakravartyFarmington$4K
- Derek LarsonCreve Coeur$605K
- Marcos RothsteinSaint Louis$350K
- Anuja JavaSaint Louis$240K
- Kevin MartinSt Louis$189K
- Alejandro AlvarezFlorissant$176K
- Gary SingerSaint Peters$170K
- Daniel CoyneSaint Louis$163K
- Tarek AlhamadSaint Louis$155K
- Tingting LiSaint Louis$130K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.